Award

NIH Reporter #1R37CA315256-01

Multi-directed prime-pull cancer immunotherapy using super-adjuvant nanoparticles

Recipient

University of Massachusetts Amherst

Award Amount

$416,468.00

Ceiling

$416,468.00

Awarded

June 29, 2026

Identifier

1R37CA315256-01

The University of Massachusetts Amherst received NIH funding to study nanoparticle-based prime-pull vaccination using synergistic STING and TLR4 adjuvants, with the goal of strengthening anti-tumor immune responses in metastatic melanoma.

Description

Funding for a project developing dual-adjuvant, dual-delivery nanoparticles to combine lymph-node priming and tumor-directed vaccination for cancer immunotherapy, using metastatic melanoma as a model.

View original record